| 000 | 01773 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250515185302.0 | ||
| 264 | 0 | _c20091124 | |
| 008 | 200911s 0 0 eng d | ||
| 022 | _a1873-5576 | ||
| 024 | 7 |
_a10.2174/156800909789271503 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDoloff, J C | |
| 245 | 0 | 0 |
_aIncreased tumor oxygenation and drug uptake during anti-angiogenic weekly low dose cyclophosphamide enhances the anti-tumor effect of weekly tirapazamine. _h[electronic resource] |
| 260 |
_bCurrent cancer drug targets _cSep 2009 |
||
| 300 |
_a777-88 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAngiogenesis Inducing Agents _xmetabolism |
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacokinetics |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoxia _xchemically induced |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, SCID |
| 650 | 0 | 4 |
_aNADPH-Ferrihemoprotein Reductase _xmetabolism |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aOxygen _xmetabolism |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTirapazamine |
| 650 | 0 | 4 |
_aTriazines _xadministration & dosage |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 700 | 1 | _aKhan, N | |
| 700 | 1 | _aMa, J | |
| 700 | 1 | _aDemidenko, E | |
| 700 | 1 | _aSwartz, H M | |
| 700 | 1 | _aJounaidi, Y | |
| 773 | 0 |
_tCurrent cancer drug targets _gvol. 9 _gno. 6 _gp. 777-88 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2174/156800909789271503 _zAvailable from publisher's website |
| 999 |
_c19152184 _d19152184 |
||